122 related articles for article (PubMed ID: 8092108)
1. Hepatocellular carcinoma during hormonotherapy for prostatic cancer.
Kattan J; Spatz A; Culine S; Terrier-Lacombe MJ; Elias D; Droz JP
Am J Clin Oncol; 1994 Oct; 17(5):390-2. PubMed ID: 8092108
[TBL] [Abstract][Full Text] [Related]
2. Hepatocellular carcinoma and treatment with cyproterone acetate.
Ohri SK; Gaer JA; Keane PF
Br J Urol; 1991 Feb; 67(2):213. PubMed ID: 1848454
[No Abstract] [Full Text] [Related]
3. A prospective, randomised study to compare goserelin acetate (Zoladex) versus cyproterone acetate (Cyprostat) versus a combination of the two in the treatment of metastatic prostatic carcinoma.
Thorpe SC; Azmatullah S; Fellows GJ; Gingell JC; O'Boyle PJ
Eur Urol; 1996; 29(1):47-54. PubMed ID: 8821690
[TBL] [Abstract][Full Text] [Related]
4. Hepatocellular carcinoma after treatment with cyproterone acetate combined with ethinyloestradiol.
Rüdiger T; Beckmann J; Queisser W
Lancet; 1995 Feb; 345(8947):452-3. PubMed ID: 7853970
[No Abstract] [Full Text] [Related]
5. Acute hepatitis induced by cyproterone acetate.
Giordano N; Nardi P; Santacroce C; Geraci S; Gennari C
Ann Pharmacother; 2001 Sep; 35(9):1053-5. PubMed ID: 11573856
[TBL] [Abstract][Full Text] [Related]
6. [Hepatocellular carcinoma in a healthy liver possibly due to long-term use of cyproterone acetate].
Manfredi S; Lenfant L; Gresset AC; Bonnotte B; Lorcerie B; Chauffert B
Presse Med; 2000 Nov; 29(36):1983. PubMed ID: 11149080
[No Abstract] [Full Text] [Related]
7. Transformation of a prostatic adenocarcinoma into squamous cell carcinoma after luteinizing hormone-releasing hormone (LHRH) agonist and radiotherapy treatment.
Ichaoui H; Nasr SB; Gargouri F; Zribi A; Hermi A; Fendri S; Balti M; Ayari J; Khiari R; Msakni I; Mansouri N; Ghozzi S; Haddaoui A
Pan Afr Med J; 2019; 34():125. PubMed ID: 33708294
[TBL] [Abstract][Full Text] [Related]
8. The association between tamoxifen and the development of hepatocellular carcinoma: case report and literature review.
Law CH; Tandan VR
Can J Surg; 1999 Jun; 42(3):211-4. PubMed ID: 10372018
[TBL] [Abstract][Full Text] [Related]
9. Secondary acute myelogenous leukemia following treatment with oral etoposide.
Katato K; Flaherty L; Varterasian M
Am J Hematol; 1996 Sep; 53(1):54-5. PubMed ID: 8813107
[No Abstract] [Full Text] [Related]
10. Suspected cross-hepatotoxicity of flutamide and cyproterone acetate.
Miquel M; Soler A; Vaqué A; Ojanguren I; Costa J; Planas R
Liver Int; 2007 Oct; 27(8):1144-7. PubMed ID: 17845544
[TBL] [Abstract][Full Text] [Related]
11. Locally advanced and metastatic prostate cancer treated with intermittent androgen monotherapy or maximal androgen blockade: results from a randomised phase 3 study by the South European Uroncological Group.
Calais da Silva F; Calais da Silva FM; Gonçalves F; Santos A; Kliment J; Whelan P; Oliver T; Antoniou N; Pastidis S; Marques Queimadelos A; Robertson C
Eur Urol; 2014 Aug; 66(2):232-9. PubMed ID: 23582949
[TBL] [Abstract][Full Text] [Related]
12. Pituitary apoplexy induced by triptorelin in patient with prostate cancer.
Guerrero-Pérez F; Marengo AP; Planas-Vilaseca A; Flores-Escobar V; Villabona-Artero C
Endocrinol Nutr; 2015 Oct; 62(8):411-2. PubMed ID: 26184059
[No Abstract] [Full Text] [Related]
13. Cyproterone acetate in the treatment of advanced prostatic cancer: retrospective analysis of liver toxicity in the long-term follow-up of 89 patients.
Hinkel A; Berges RR; Pannek J; Schulze H; Senge T
Eur Urol; 1996; 30(4):464-70. PubMed ID: 8977068
[TBL] [Abstract][Full Text] [Related]
14. Severe hepatitis caused by cyproterone acetate.
Blake JC; Sawyerr AM; Dooley JS; Scheuer PJ; McIntyre N
Gut; 1990 May; 31(5):556-7. PubMed ID: 2140997
[TBL] [Abstract][Full Text] [Related]
15. [Diethylstilbestrol-induced liver cancer?].
Rosinus V; Maurer R
Schweiz Med Wochenschr; 1981 Jul; 111(30):1139-42. PubMed ID: 6267685
[TBL] [Abstract][Full Text] [Related]
16. The combination of cyproterone acetate and low dose diethylstilbestrol in the treatment of advanced prostatic carcinoma.
Goldenberg SL; Bruchovsky N; Rennie PS; Coppin CM
J Urol; 1988 Dec; 140(6):1460-5. PubMed ID: 2973529
[TBL] [Abstract][Full Text] [Related]
17. [Position of the German Society of Gynecology and Obstetrics on the intended recall of approved CPA-containing drugs].
Hammerstein J; Rabe T; Runnebaum B
Gynakol Geburtshilfliche Rundsch; 1995; 35(1):49-50. PubMed ID: 7727976
[No Abstract] [Full Text] [Related]
18. [Preventive effect of chlormadinone acetate on flare-up phenomenon in advanced prostate cancer administered with a luteinizing hormone-releasing hormone analogue].
Sato N; Kotake T; Masai M; Sakai S; Ito H
Hinyokika Kiyo; 2000 Jan; 46(1):1-7. PubMed ID: 10723656
[TBL] [Abstract][Full Text] [Related]
19. Systemic sclerosis following anti-androgenic treatment for prostatic adenocarcinoma.
Giordano N; Magaro L; Fattorini L; Marcucci P; Battisti E; Fioravanti A; Marcolongo R
Clin Rheumatol; 1993 Mar; 12(1):81-4. PubMed ID: 8467617
[TBL] [Abstract][Full Text] [Related]
20. [Hepatotoxicity induced by cyproteron acetate in the prostate carcinoma treatment - a case report].
Vodička M; Sálek T; Röderová E; Cerný D
Klin Onkol; 2013; 26(1):47-8. PubMed ID: 23528173
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
